14 results on '"Fayette, J."'
Search Results
2. Immunotherapy in head and neck cancer: a new paradigm.
- Author
-
Reverdy T, Karabakakian A, Gau M, and Fayette J
- Subjects
- Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, B7-H1 Antigen metabolism, CTLA-4 Antigen immunology, Head and Neck Neoplasms mortality, Humans, Interferon-gamma genetics, Nivolumab therapeutic use, Treatment Outcome, Head and Neck Neoplasms therapy, Immunotherapy methods
- Published
- 2018
- Full Text
- View/download PDF
3. Chemotherapy for recurrent/metastatic head and neck cancers.
- Author
-
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, and Fayette J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms pathology, Humans, Immunotherapy methods, Neoplasm Metastasis, Neoplasm Recurrence, Local pathology, Randomized Controlled Trials as Topic, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this protocol in ongoing trials and the association of cisplatin, docetaxel, and cetuximab appears to be the most efficient. The human papilloma virus is very likely a favorable prognostic factor. Immunotherapy with nivolumab or pembrolizumab is now a new standard of treatment in second line after yielding an improvement in overall survival, but predictive markers of efficacy are needed to refine the selection of patients. The combination of paclitaxel and buparlisib appears to be promising.
- Published
- 2017
- Full Text
- View/download PDF
4. Chemotherapy for localized head and neck squamous cell cancers.
- Author
-
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, and Fayette J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell pathology, Cisplatin administration & dosage, Head and Neck Neoplasms pathology, Humans, Randomized Controlled Trials as Topic, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy
- Abstract
Concomitant chemotherapy with cisplatin (100 mg/m every 3 weeks) improves outcome for high-risk patients in the postoperative setting and for inoperable disease. Toxicity is increased. Other schemes of potentiation are sometimes used to reduce toxicity, but efficiency is diminished. Cetuximab also improves outcome, but there has been no direct comparison with cisplatin. Immunotherapy is currently being evaluated in association with radiation therapy. Trials are ongoing to evaluate the impact of de-escalation for human papillomavirus-positive patients. The association of docetaxel, cisplatin, and 5-fluorouracil is the standard of induction; it is also the standard treatment for laryngeal preservation. Many trials have attempted to compare the concomitant approach with the sequential treatment; none have managed to show a difference between the two. After induction chemotherapy, there is still no standard of potentiation of radiotherapy.
- Published
- 2017
- Full Text
- View/download PDF
5. A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
- Author
-
Céruse P, Cosmidis A, Belot A, Rabilloud M, Fuchsmann C, Poupart M, Ramade A, Tartas S, Favrel V, Pommier P, Zrounba P, and Fayette J
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell pathology, Cisplatin administration & dosage, Cisplatin therapeutic use, Combined Modality Therapy, Disease-Free Survival, Docetaxel, Female, Fluorouracil administration & dosage, Fluorouracil therapeutic use, Humans, Induction Chemotherapy, Male, Middle Aged, Neoplasm Recurrence, Local, Paranasal Sinus Neoplasms pathology, Retrospective Studies, Taxoids administration & dosage, Taxoids therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell radiotherapy, Organ Sparing Treatments, Paranasal Sinus Neoplasms drug therapy, Paranasal Sinus Neoplasms radiotherapy, Pyriform Sinus pathology
- Abstract
No specific study has evaluated the role of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) followed by radiotherapy in pyriform sinus cancer, which are often included in studies focusing on laryngeal and hypopharyngeal cancer. We assessed the proportion of patients treated sequentially for a pyriform sinus cancer with a preserved larynx. Overall survival, event-free survival (EFS), survival with 'local control', and treatment tolerance were assessed as well. We retrospectively reviewed 88 patients with advanced pyriform sinus squamous cell carcinoma treated with DCF between 2005 and 2010. After induction, radiation could be potentiated with cetuximab or cisplatin. Most patients (82%) had been treated with organ preservation intent. The response rate to DCF was 85%, including 42% with complete response. Primary tumor was operated in 13 patients (eight with total laryngectomy). Radiotherapy had been delivered to 78 (89%) patients (30 with cisplatin, 39 with cetuximab). Potentiation had been achieved as planned in 52 and 79% of patients treated with cisplatin and cetuximab, respectively. Twenty-three local and three neck recurrences were found. Median overall survival was 16.8 months and 38.3% at 3 years. EFS at 3 years was 29.1% with a hazard ratio for partial responders versus nonresponders of 0.18 (P<0.001), and 0.13 (P<0.001) for complete responders versus nonresponders. Thirty-five percent of patients were alive with their larynx preserved at 3 years. This study confirms the efficacy of induction followed by chemoradiation for pyriform sinus cancer and that response to DCF is predictive of EFS.
- Published
- 2014
- Full Text
- View/download PDF
6. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
- Author
-
Fayette J, Bonnin N, Ferlay C, Lallemant B, Ramade A, Favrel V, Zrounba P, Chabaud S, Pommier P, Poupart M, and Céruse P
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cetuximab, Cisplatin administration & dosage, Cisplatin adverse effects, Cisplatin therapeutic use, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Male, Middle Aged, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Taxoids administration & dosage, Taxoids adverse effects, Taxoids therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell therapy, Chemoradiotherapy methods, Head and Neck Neoplasms therapy
- Abstract
Neoadjuvant TPF (docetaxel, cisplatin, 5-fluorouracil), followed by radiotherapy or chemoradiotherapy with weekly carboplatin, increases overall survival and organ preservation. We assessed whether TPF could be used in routine practice and whether radiotherapy potentiated with cisplatin or cetuximab was feasible and could increase survival. We retrospectively reviewed 157 patients with advanced head and neck squamous cell carcinoma treated with TPF in four French institutions between May 2005 and March 2009. After induction, operable patients had undergone surgery and were irradiated, and potentiated in some cases with cetuximab or cisplatin. Most patients (79%) had been treated with organ preservation strategies. The two most common sites were the hypopharynx (34%) and the oropharynx (30%). The response rate to TPF was 84%, including 26% with a complete response. Radiotherapy had been provided to 144 (92%) patients (of whom 17 had received radiotherapy alone, 46 had received q3w cisplatin, 30 had received q1w cisplatin, and 37 had received cetuximab). Potentiation had been achieved as planned in 59, 63, and 62% of patients treated with q3w cisplatin, q1w cisplatin, and cetuximab, respectively. After a median follow-up of 39.9 months, the median overall survival was 43 months. No significant difference was observed in progression-free survival or overall survival according to the type of potentiation. This study confirms the efficacy and tolerability of TPF induction, followed by chemoradiation, with outcomes similar to those for patients irradiated without induction. The best potentiation of radiotherapy after induction has not yet been determined.
- Published
- 2013
- Full Text
- View/download PDF
7. Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
- Author
-
Péron J, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, and Fayette J
- Subjects
- Adult, Aged, Aged, 80 and over, Capecitabine, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell secondary, Deoxycytidine adverse effects, Deoxycytidine therapeutic use, Disease-Free Survival, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Head and Neck Neoplasms pathology, Head and Neck Neoplasms secondary, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local pathology, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Survival Rate, Carcinoma, Squamous Cell drug therapy, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives, Head and Neck Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Unlabelled: The objective of this study was to evaluate the efficacy and tolerability of capecitabine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral capecitabine according to good clinical practice. Efficacy and safety outcomes were analyzed retrospectively. The response and adverse events rates and their exact confidence intervals (CIs) were calculated. Survival distributions were estimated using the Kaplan-Meier method. Twenty-nine patients were included in the study. Twenty-five patients (86%) had received at least three previous lines of chemotherapy. The disease control rate was 48% (95% CI: 29-67%). The median progression-free survival was 2.0 months (95% CI: 0.1-3.9 months) and the median overall survival was 7.0 months (95% CI: 4.1-9.9 months). Hand-foot syndrome, fatigue, and mucositis were the most frequent severe side effects. No patient died, and only three patients discontinued treatment because of side effects. Capecitabine seems to be an active and well-tolerated regimen, even in heavily pretreated, frail patients., Level of Evidence: 2C 'Outcomes Research'.
- Published
- 2012
- Full Text
- View/download PDF
8. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
- Author
-
Péron J, Ceruse P, Lavergne E, Buiret G, Pham BN, Chabaud S, Favier B, Girodet D, Zrounba P, Ramade A, and Fayette J
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Cetuximab, Cisplatin administration & dosage, Cisplatin adverse effects, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Head and Neck Neoplasms mortality, Head and Neck Neoplasms pathology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Paclitaxel administration & dosage, Paclitaxel adverse effects, Paclitaxel therapeutic use, Retrospective Studies, Treatment Failure, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Cisplatin therapeutic use, Head and Neck Neoplasms drug therapy, Neoplasm Recurrence, Local prevention & control
- Abstract
The addition of cetuximab (CTX) to the combination of cisplatin and 5-fluorouracil increases the overall survival (OS) in recurrent/metastatic head and neck squamous cell carcinoma. Only a few patients are eligible for this treatment because of its toxicity. The combination of CTX and paclitaxel (TXL) could be included in sequential treatment strategies. Patients were treated with CTX (400/250 mg/m) and TXL (60-80 mg/m) weekly until disease progression or unacceptable toxicity. Efficacy and safety outcomes were determined retrospectively. A total of 42 patients were included in this analysis. The overall response rate was 38% [95% confidence interval (CI); 23-53%]. The disease control rate with TXL and CTX combination was 74%. Seven (17%) patients progressed before the first evaluation. The median progression-free survival was 3.9 months [95% CI; 3.1-4.7 months] and the median OS was 7.6 months [95% CI; 5.3-9.9 months]. Neurotoxicity and skin rash were the most frequent grade≥2 toxicities, reported in 17 and 12% of patients, respectively. Previous chemotherapy seems to be associated with a lower response rate and progression-free survival but not with the OS. The combination of CTX and TXL was an active and well-tolerated treatment in this series of patients with a poor prognosis and who were mostly symptomatic.
- Published
- 2012
- Full Text
- View/download PDF
9. Current chemotherapies for recurrent/metastatic head and neck cancer.
- Author
-
Molin Y and Fayette J
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms pathology, Humans, Neoplasm Metastasis, Neoplasm Recurrence, Local, Quality of Life, Survival Rate, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy
- Abstract
Surgery and radiotherapy are generally not an option for recurrent/metastatic head and neck squamous cell carcinoma. Chemotherapy is the only possible treatment. The five major drugs active in monotherapy are methotrexate, cisplatin, 5-fluorouracil (5-FU), cetuximab (an antiepidermal growth factor receptor antibody) and taxanes (paclitaxel or docetaxel). They allow 10-25% response with a median survival of approximately 6-8 months. Various chemotherapy doublets may achieve higher response rates, up to 45-50%, but overall survival remains unchanged. As recurrent patients are often symptomatic, better response is associated with better quality of life and the standard treatment for patients with performance status 0-1 is the combination of cisplatin and 5-FU. Recently, the triplet cisplatin-5-FU-cetuximab, which has been shown to result in an increased response rate and a significantly better median survival of 10.4 months, has become the new treatment standard.
- Published
- 2011
- Full Text
- View/download PDF
10. Induction chemotherapy in head and neck cancer: a new paradigm.
- Author
-
Pointreau Y, Atean I, Fayette J, Calais G, and Lefebvre JL
- Subjects
- Carcinoma, Squamous Cell pathology, Chemotherapy, Adjuvant methods, Combined Modality Therapy, Head and Neck Neoplasms pathology, Humans, Neoadjuvant Therapy methods, Neoplasm Staging, Prognosis, Antineoplastic Agents administration & dosage, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy
- Abstract
Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a high cure rate while preserving functions. Treatment strategies are designed according to the disease stage, primary site, operable status, patient age, and performance status. Surgery, radiation therapy, chemotherapy, and more recently molecular-targeted therapies are part of these strategies, but their sequence remains to be defined. Over the last 30 years, induction chemotherapy has attained an important position in the management of patients with locally advanced squamous cell carcinoma, particularly since the introduction of taxanes. The decision to deliver induction chemotherapy (and its intensification) must be considered in the light of other treatments aiming at better locoregional control (normofractioned radiotherapy, accelerated or hyperfractionated radiotherapy, addition of concurrent chemotherapy, or of targeted therapy) with or without adjuvant treatment. This review summarizes the rationale, these data, and perspectives on induction chemotherapy-based strategies.
- Published
- 2011
- Full Text
- View/download PDF
11. Head and neck squamous cell carcinomas.
- Author
-
Fayette J
- Subjects
- Carcinoma, Squamous Cell physiopathology, Combined Modality Therapy, Head and Neck Neoplasms physiopathology, Humans, Risk Factors, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy
- Published
- 2011
- Full Text
- View/download PDF
12. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution.
- Author
-
Fayette J, Montella A, Chabaud S, Bachelot T, Pommier P, Girodet D, Racadot S, Montbarbon X, Favier B, and Zrounba P
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, Cetuximab, Humans, Male, Middle Aged, Retrospective Studies, Survival Analysis, Treatment Outcome, Antineoplastic Agents, Phytogenic therapeutic use, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Paclitaxel therapeutic use
- Abstract
The standard first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma is cisplatin-based chemotherapy, but taxanes can also be beneficial after progression or in patients not eligible for cisplatin. The objective of this retrospective study was to evaluate paclitaxel in this population. We reviewed 66 patients who were treated with paclitaxel at a single institution (Lyon, France) between January 2003 and November 2008. Paclitaxel was administered as first, second or more line of treatment; alone or in combination with carboplatin or cetuximab; every 3 weeks (175 mg/m(2)) or weekly (80 mg/m(2)). Forty-six (70%) patients received paclitaxel as first-line therapy after relapse and 26 (39%) patients as monotherapy. The objective response rate was 30% [95% confidence interval (CI): 20-43%]; 37% (95% CI: 23-52%) in the first line after relapse, and 20% (95% CI: 4-48%) in the second line. Rates were 19% (95% CI: 7-39%) after monotherapy and 36% (95% CI: 20-55%) after combination with carboplatin. Two of the six patients receiving cetuximab had a partial response. The overall survival of all patients was 7.2 months (95% CI: 5.2-8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates.
- Published
- 2010
- Full Text
- View/download PDF
13. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
- Author
-
Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P, Thiesse P, Méeus P, Sunyach MP, Vaz G, Ray-Coquard I, Ranchère D, Decouvelaere AV, Alberti L, Pérol D, and Blay JY
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Alkylating adverse effects, Dioxoles administration & dosage, Dioxoles adverse effects, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness, Proportional Hazards Models, Retrospective Studies, Sarcoma pathology, Tetrahydroisoquinolines administration & dosage, Tetrahydroisoquinolines adverse effects, Trabectedin, Young Adult, Antineoplastic Agents, Alkylating therapeutic use, Compassionate Use Trials, Dioxoles therapeutic use, Sarcoma drug therapy, Tetrahydroisoquinolines therapeutic use
- Abstract
Trabectedin was recently approved for patients failing doxorubicin, the standard treatment for advanced/metastatic sarcoma. This retrospective study aimed to compare trabectedin efficacy between compassionate use in unselected patients and clinical trials. From May 1999 to January 2006, 92 patients were treated at the Centre Léon Bérard, either in phase II studies or on a named patient compassionate basis. All cases were retrospectively analyzed to assess trabectedin efficacy in terms of response, progression-free, and overall survival.The objective response rate was 10% (N=9): 4% (N=2) for patients treated in compassionate use program and 16% (N=7) for those in clinical trials (P=0.18); 26 (28%) patients had stable disease for at least 6 months, 11 (23%) in the compassionate group and 15 (33%) in clinical trials. Median progression-free and overall survivals were, respectively, 2.2 [95% confidence interval (CI): 1.9-3.6] and 8.9 (95% CI: 6.4-14.2) months for all patients, 2.3 (95% CI: 1.9-4.3) and 10.4 (95% CI: 6.9-24.2) months for patients in clinical trials and 1.8 (95% CI: 1.4-3.4) and 6.4 (95% CI: 3.3-14.2) months for patients under compassionate treatment. In this retrospective analysis, the reported grade 3-4 toxicities were increased transaminase (34 patients, 37%) and neutropenia (38 patients; 42%). Higher efficacy was observed in phase II studies than with compassionate treatment, but no significant difference remained after adjustment in multivariate analysis for performance status, a well-established prognosis factor. The safety and tolerability of trabectedin shown in clinical trials is confirmed for patients in real-life situation treated in compassionate use programs, but its benefit is higher for patients with performance status 0-1.
- Published
- 2010
- Full Text
- View/download PDF
14. Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004.
- Author
-
Fayette J and Blay JY
- Subjects
- Apoptosis, Humans, Mutation, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm genetics, Sarcoma genetics, Soft Tissue Neoplasms genetics
- Abstract
Purpose of Review: Sarcomas are generally managed through a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Metastatic tumor cells frequently develop resistance to cytotoxic agents. Several molecular mechanisms of drug resistance have been uncovered recently., Recent Findings: Among genes governing the apoptosis pathway, overexpression of the bcl2 family or mutations of p53 have recently been reported to be involved in drug resistance in sarcoma. The multidrug resistance genes are involved in the efflux of chemotherapeutic agents. Identification of members of this family of genes may predict resistance for developing new strategies. Several histologic subtypes of sarcomas have specific mechanisms of resistance. Methotrexate is one of the four active drugs for osteosarcoma and penetrates in tumor cell through specific carrier (reduced folate carrier) whose levels of expression or changes in amino acid sequence correlate to resistance to methotrexate. Specific molecular alteration defining nosological entities among sarcoma also correlates to drug resistance. Thirty percent of human sarcomas are characterized by specific translocations that may predict, for specific subtypes, survival and response to treatment. Finally, gastrointestinal tumors harbor specific activating mutations in KIT or PDGFRA genes, which are responsive to imatinib. Specific mutations of the KIT and PDGFRA genes have now repeatedly been found correlated to response or resistance to imatinib., Summary: The molecular alterations present in tumor cells predict influence sensitivity or resistance to chemotherapy. Ultimately, this may delineate specific therapeutic strategies for both cytotoxic and targeted therapies in sarcomas.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.